Dr. Doebele is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8000 Jarvis Ave.
Ste 204
Newark, CA 94560Phone+1 510-255-2171
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007- University of ChicagoResidency, Internal Medicine, 2001 - 2004
Perelman School of Medicine at the University of PennsylvaniaClass of 2001
Certifications & Licensure
CO State Medical License 2008 - 2025
IL State Medical License 2001 - 2008
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer Start of enrollment: 2012 Jan 23
- Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Start of enrollment: 2017 Dec 13
Publications & Presentations
PubMed
- Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.David Gonzalez-Martinez, Lee Roth, Thomas R Mumford, Juan Guan, Anh Le
Nature Communications. 2024-11-02 - A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuro...Kyle F Concannon, Bonnie S Glisson, Robert C Doebele, Chao Huang, Marcelo Marotti
Clinical Lung Cancer. 2024-11-01 - 7 citationsNeoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.Collin M Blakely, Anatoly Urisman, Matthew A Gubens, Claire K Mulvey, Greg M Allen
Journal of Clinical Oncology. 2024-09-10
Lectures
- Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and c...2019 ASCO Annual Meeting - 6/1/2019
- Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome's positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Chutes & Ladders—Another Novartis Exec Answers the Biotech Call, This Time for Gene Therapy Startup TevardMay 21st, 2021- BioSpace Movers & Shakers, May 21May 20th, 2021
- Rain Therapeutics Strengthens the Board of Directors and Scientific Advisory Board with Key Appointments of Leading Industry and Research ExpertsApril 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
